Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives

•Treatment of advanced gastric cancers remains an area of great unmet need.•Anti–PD-1/PD-L1 antibodies have shown clinical activity in gastric cancers.•Phase 3 trials are assessing anti–PD-1/PD-L1 monotherapy and combination regimens.•First-line, maintenance, and later-line treatment strategies are...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer treatment reviews 2018-05, Vol.66, p.104-113
Hauptverfasser:	Taieb, Julien, Moehler, Markus, Boku, Narikazu, Ajani, Jaffer A., Yañez Ruiz, Eduardo, Ryu, Min-Hee, Guenther, Silke, Chand, Vikram, Bang, Yung-Jue
Format:	Artikel
Sprache:	eng
Schlagworte:	Gastric Gastroesophageal junction Immune checkpoint inhibitors Immunotherapy PD-1/PD-L1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!